Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Structural characterization of monoclonal antibodies targeting C-terminal Ser region of phosphorylated tau protein.

MAbs. 2019; 
ChukwuJessica E,CongdonErin E,SigurdssonEinar M,KongXiang-
Products/Services Used Details Operation
Peptide Synthesis … support the rapidly growing practice of using tau antibodies as a potential disease-modifying treatment for AD and other tauopathies. Materials and methods Monoclonal antibody and synthetic peptides MAbs 8B2, 6B2, and 4E6 were generated by GenScript as previously … Get A Quote

摘要

Targeting tau with immunotherapies is currently the most common approach taken in clinical trials of patients with Alzheimer's disease. The most prominent pathological feature of tau is its hyperphosphorylation, which may cause the protein to aggregate into toxic assemblies that collectively lead to neurodegeneration. Of the phospho-epitopes, the region around Ser/Ser has received particular attention for therapeutic targeting because of its prominence and stability in diseased tissue. Herein, we present the antigen-binding fragment (Fab)/epitope complex structures of three different monoclonal antibodies (mAbs) that target the pSer tau epitope region. Most notably, these structures reveal an antigen co... More

关键词

Alzheimer’s disease,Monoclonal antibody,antibody-antigen complex,phospho-epitope,tau pro
XML 地图